Jounce Therapeutics, Inc. (JNCE)
| Market Cap | 237.19M |
| Revenue (ttm) | 25.37M |
| Net Income (ttm) | -101.70M |
| Shares Out | 51.67M |
| EPS (ttm) | -1.82 |
| PE Ratio | n/a |
| Forward PE | 19.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,837 |
| Open | 4.33 |
| Previous Close | 4.36 |
| Day's Range | 4.29 - 4.64 |
| 52-Week Range | 4.06 - 9.81 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 16.61 (+261.9%) |
| Earnings Date | May 5, 2022 |
About JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811...
Financial Performance
In 2021, JNCE's revenue was $26.91 million, a decrease of -56.84% compared to the previous year's $62.34 million. Losses were -$90.87 million, 107.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 16.61, which is an increase of 261.87% from the latest price.
News
Jounce Therapeutics Reports First Quarter 2022 Financial Results
- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 -
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeu...
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 -
Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wedne...
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Lags Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -47.50% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 -
Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, ...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inh...
- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts –
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
Jounce Therapeutics to Present at Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 78.95% and 167.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August ...
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update...
- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021-
Why Jounce Therapeutics Bounced Higher Today
The company gets a regulatory nod that will put $25 million in its pocket.
Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc (NASDAQ: G...
Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American ...
- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas -